Mechanism of Action of L THP as an Alternative Therapy for Cocaine Addiction
L THP 作为可卡因成瘾替代疗法的作用机制
基本信息
- 批准号:8369115
- 负责人:
- 金额:$ 45.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAdverse effectsAffinityAftercareAlcohol abuseAlkaloidsAlternative TherapiesAmphetaminesAnalgesicsAnimal ModelAnimalsAwardBehaviorBehavioralBindingBiochemical PharmacologyBiological FactorsBrainChinaClinicalClinical TrialsCocaineCocaine DependenceCorydalisCuesDopamine ReceptorDrug AddictionDrug KineticsDrug abuseEvaluationFamiliarityFundingGrantHepatocyteHeroinHeroin DependenceIn VitroInvestigationIon ChannelIsoquinolinesLaboratoriesLeadLiteratureMarylandMediatingMetabolismMethamphetamineMinorMono-SMotor ActivityMusNational Center for Complementary and Alternative MedicineNational Institute of Drug AbuseNeurotransmitter ReceptorOpiumPainPharmaceutical PreparationsPharmacotherapyProdrugsPropertyPsychological reinforcementPublic HealthRattusRecording of previous eventsResearchRewardsSedation procedureSelf AdministrationSerumSmokingSourceStressTechniquesTimeUnited States National Institutes of HealthUniversitiesWithdrawalanalog Lbasebehavioral sensitizationchemical synthesiscravingdrug candidatedrug developmentdrug discoverydrug metabolismdrug seeking behaviorhypnoticin vivoneurochemistrypreferenceprogramsreceptorreceptor bindingsedativetetrahydropalmatine
项目摘要
DESCRIPTION (provided by applicant): Cocaine addiction is a vexing public health problem for which no effective pharmacotherapies have been developed. Naturally derived bioactive compounds have been a rich source for modern drug development. Under our CERC program project "Alternative Therapies for Alcohol and Drug Abuse" (P01-AT- 002038) funded by NCCAM, eight isoquinoline alkaloids, including L-tetrahydropalmatine (L-THP), were isolated and characterized from tubers of Corydalis yanhuso, which is one of the five components of an herbal remedy (NPI-025) used in China to treat opium smoking for over 150 years. Interestingly, L-THP has been used clinically in China for more than 30 years as an analgesic with sedative/hypnotic properties and recently to treat heroin addiction. In animal models, L-THP reduced reinforcing property of cocaine and reinstatement of cocaine seeking following withdrawal. Importantly, L-THP itself had no rewarding effect, suggesting absence of abuse liability. Recently, Dr. Jia-Bei Wang of the University of Maryland received an NIH grant to conduct a clinical trial on L-THP for treatment of cocaine addiction in the US. Despite its long history of clinical use, the mechanisms of action of L-THP are not clear. Although some in vivo effects appear to be mediated by dopamine receptors, we found that L-THP had low or no affinity for the five subtypes (D1- D5) of DA receptors (see C.1.2). In addition, it did not bind t about 60 neurotransmitter receptors, ion channels, and transporters involved in pain modulation and drug addiction that we screened (see C.1.2). Following L-THP administration in mice or rats, we identified in serum the mono-demethylated analogs L- corypalmine (L-CP) and L-corydalmine (L-CD) to be the major metabolites and L-isocorypalmine (L-ICP) to be a minor metabolite (see C.1.3). We also found that L-ICP had moderate to high affinity for DA receptors (see C.1.4) and reduced cocaine-induced hyperlocomotion, behavioral sensitization and conditioned place preference (See C.1.5-1.8). Thus, we hypothesize that L-THP is a prodrug and its effects are due to demethylated metabolites acting on multiple DA receptors to modulate cocaine-induced behaviors. Consequently, we propose to further pharmacologically characterize L-THP and its demethylated metabolites to gain a better understanding of the mechanisms of action. Our specific aims are to (1) prepare L-THP and chemically synthesize its metabolites in sufficient quantity for pharmacological studies; (2) determine the metabolism and pharmacokinetic profiles of L-THP; (3) identify pharmacological activity of major metabolites at DA receptors and other targets; and (4) examine the effects of L-THP and its metabolites on cocaine self administration and reinstatement of drug seeking following withdrawal. The proposed research will enhance the understanding of mechanisms of action of L-THP, which may open a new avenue for mechanism-based drug discovery for cocaine addiction. As one of the major side effects of L-THP is sedation, our proposed study may yield candidate drugs with less sedation, as we have demonstrated for L-ICP.
PUBLIC HEALTH RELEVANCE: The overall objective is to study the mechanism of action of the natural product L- tetrahydropalmatine (L-THP) as an alternative therapy against cocaine dependence, for which there is no satisfactory pharmacotherapy. Studies in our laboratory and others have shown that L-THP reduced cocaine self- administration, reinstatement of cocaine seeking, cocaine-induced conditioned place preference (CPP), and brain-stimulation enhancement, while having no intrinsic rewarding effect, which suggests absence of abuse liability. Consequently, we propose to further pharmacologically characterize its demethylated metabolites to gain a better understanding of the mechanism of action and to support our hypothesis that it is a prodrug and its effects are due to demethylated metabolites acting on multiple DA receptors to modulate cocaine-induced behaviors and neurochemical changes.
描述(由申请人提供):可卡因成瘾是一个令人烦恼的公共卫生问题,尚未开发出有效的药物治疗。天然衍生的生物活性化合物已成为现代药物开发的丰富来源。在我们的CERC计划项目“酒精和药物滥用的替代疗法”(P01-AT- 002038)由NCCAM资助,八个异喹啉生物碱,包括L-四氢巴马汀(L-THP),分离和表征从Cordyanhuso的块茎,这是中国用于治疗鸦片吸烟超过150年的草药(NPI-025)的五个成分之一。有趣的是,L-THP作为具有镇静/催眠特性的镇痛药在中国临床使用已有30多年,最近用于治疗海洛因成瘾。在动物模型中,L-THP降低可卡因的增强特性和戒断后可卡因寻求的恢复。重要的是,L-THP本身没有奖励效应,表明没有滥用责任。最近,马里兰州大学的王佳蓓博士获得了美国国立卫生研究院的资助,在美国进行了一项关于L-THP治疗可卡因成瘾的临床试验。尽管L-THP的临床应用历史悠久,但其作用机制尚不清楚。尽管一些体内效应似乎是由多巴胺受体介导的,但我们发现L-THP对DA受体的五种亚型(D1- D5)具有低亲和力或没有亲和力(见C.1.2)。此外,它不结合我们筛选的约60种参与疼痛调节和药物成瘾的神经递质受体、离子通道和转运蛋白(见C.1.2)。在小鼠或大鼠中给予L-THP后,我们在血清中鉴定出单脱甲基类似物L-紫堇碱(L-CP)和L-紫堇达明(L-CD)为主要代谢产物,L-异紫堇碱(L-ICP)为次要代谢产物(见C.1.3)。我们还发现L-ICP对DA受体具有中等至高亲和力(见C.1.4),并减少可卡因诱导的过度运动、行为敏化和条件性位置偏爱(见C.1.5-1.8)。因此,我们假设L-THP是一种前药,其作用是由于去甲基代谢物作用于多种DA受体来调节可卡因诱导的行为。因此,我们建议进一步研究L-THP及其脱甲基代谢产物的特性,以更好地了解其作用机制。我们的具体目标是(1)制备足够量的L-THP并化学合成其代谢产物用于药理学研究;(2)确定L-THP的代谢和药代动力学特征;(3)鉴定主要代谢产物对DA受体和其他靶点的药理活性;(4)研究L-THP及其代谢产物对可卡因自我给药和戒断后复吸的影响。拟议的研究将增进对L-THP作用机制的理解,这可能为基于机制的可卡因成瘾药物发现开辟新途径。由于L-THP的主要副作用之一是镇静,我们提出的研究可能会产生镇静作用较小的候选药物,正如我们已经证明的L-ICP。
公共卫生相关性:总体目标是研究天然产物L-四氢巴马汀(L-THP)作为对抗可卡因依赖的替代疗法的作用机制,对于可卡因依赖没有令人满意的药物疗法。我们实验室和其他实验室的研究表明,L-THP减少了可卡因自我给药、可卡因寻求的恢复、可卡因诱导的条件性位置偏好(CPP)和脑刺激增强,同时没有内在的奖励效应,这表明没有滥用倾向。因此,我们建议进一步研究其去甲基化代谢产物,以更好地了解其作用机制,并支持我们的假设,即它是一种前药,其作用是由于去甲基化代谢产物作用于多种DA受体,以调节可卡因诱导的行为和神经化学变化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID Yue-Wei LEE其他文献
DAVID Yue-Wei LEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID Yue-Wei LEE', 18)}}的其他基金
Mechanism of Action of L THP as an Alternative Therapy for Cocaine Addiction
L THP 作为可卡因成瘾替代疗法的作用机制
- 批准号:
8686757 - 财政年份:2012
- 资助金额:
$ 45.72万 - 项目类别:
Mechanism of Action of L THP as an Alternative Therapy for Cocaine Addiction
L THP 作为可卡因成瘾替代疗法的作用机制
- 批准号:
8858518 - 财政年份:2012
- 资助金额:
$ 45.72万 - 项目类别:
Mechanism of Action of L THP as an Alternative Therapy for Cocaine Addiction
L THP 作为可卡因成瘾替代疗法的作用机制
- 批准号:
8537821 - 财政年份:2012
- 资助金额:
$ 45.72万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
6861518 - 财政年份:2004
- 资助金额:
$ 45.72万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 45.72万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 45.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 45.72万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 45.72万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Discovery Grants Program - Individual